{"id":14698,"date":"2026-05-13T10:33:54","date_gmt":"2026-05-13T08:33:54","guid":{"rendered":"https:\/\/optano.com\/?p=14698"},"modified":"2026-05-13T10:33:56","modified_gmt":"2026-05-13T08:33:56","slug":"insights-new-us-customs-plans-for-the-pharmaceutical-industry","status":"publish","type":"post","link":"https:\/\/optano.com\/en\/media\/insight\/2\/insights-neue-us-zollplaene-fuer-die-pharmaindustrie\/","title":{"rendered":"Insights: New U.S. Customs Plans for the Pharmaceutical Industry"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

New U.S. customs plans for the pharmaceutical industry<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

When Tariffs Suddenly Put Supply Chains in Question<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

What seems like a foreign trade issue quickly becomes a planning problem in the pharmaceutical industry. Since the new US tariff plans, for many pharmaceutical companies, it's no longer just the amount of tariffs that is relevant, but the question of whether their supply chain can react quickly enough to new regulations.<\/p>

Those who produce medicines for the US market are not dealing with a simple surcharge. Depending on the product, patent status, origin, and company structure, different requirements apply. This quickly turns a trade policy signal into an operational question: Which products can continue as before, where will margin pressure arise, and at what point will a previously stable structure collapse?<\/p>

For pharmaceutical companies in Europe, this is highly relevant. The USA was the most important sales market outside the EU for pharmaceutical products in 2025. If the framework conditions there shift, it is not enough to just look at prices or tariffs. Then the entire decision-making structure behind it must be re-evaluated.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201eNew US customs plans will affect pharmaceutical companies not only on price but also on their entire supply chain logic.\u201c<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

In the pharmaceutical industry, tariffs never just affect costs<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The problem begins long before crossing the border<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In many industries, a new tariff rate is initially perceived as a cost issue. In the pharmaceutical industry, this perspective is too short-sighted. As soon as a patented product becomes more expensive or regulatorily complex for an important export market, several decisions are set in motion simultaneously: production allocation, active ingredient supply, packaging and release logic, safety stocks, prioritization of scarce capacities, and, in case of doubt, even the question of which market will be served first.<\/p>

In addition, the US regulation is differentiated. It is not a blanket 100 percent case for everything that goes from Europe to the USA. It is precisely this differentiation that makes the situation operationally challenging. Those who plan too broadly simplify the problem incorrectly. Those who calculate manually for too long cannot keep up with the dynamics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201eThe real risk lies less in individual tariff rates and more in rigid, difficult-to-replan networks.\u201c<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The real vulnerability lies deeper<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The new customs plans are hitting an industry whose supply chains were already under pressure. European institutions have long been concerned with the dependence on active pharmaceutical ingredients (APIs), limited production capacities, shortages of critical medicines, and how to organize supply security beyond traditional efficiency logic. The fact that strategic stockpiling, supply chain transparency, and more resilient production structures are being discussed in parallel shows that the vulnerability is structural.<\/p>

So, a company can operate in a regulatorily compliant manner and still fall into an operational trap. Not because a factory suddenly shuts down, but because the existing structure was built for stability, not for differentiated customs regimes, sudden customs increases, and volatile allocation decisions.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The critical moment is rarely spectacular<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This becomes apparent in a simple scenario: a patented specialty product is further delivered from a European location to the USA. The active ingredient is scarce, release processes are tightly scheduled, and additional inventory cannot be built up indefinitely due to limited shelf life and high capital commitment. As soon as the dependence on the US market changes, it is no longer sufficient to enter the customs tariff in an Excel column. Then, a new decision must be made on how to allocate material, whether production steps should be reassigned, and which supply chain makes economic sense without jeopardizing regulatory stability.<\/p>

This is precisely the real problem: the bottleneck lies not in individual tariffs, but in the lack of ability to reliably reorganize multiple interdependent decisions simultaneously.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201eOptimization becomes relevant when costs, supply, approvals, and capacities need to be rebalanced simultaneously.\u201c<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

What makes mathematical optimization different in this situation<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

From the Individual Problem to Decision Logic<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mathematical optimization isn't just helpful because it computes faster. Its value lies in transforming a complex situation into a structured decision-making logic. Instead of looking at costs, inventory, utilization, or service sequentially, it evaluates these factors jointly.<\/p>

The question then is no longer just: \u201eWhat is the tariff rate for this product?\u201c But rather: \u201eWhich combination of production location, material flow, inventory position, capacity utilization, and market allocation leads to the best resilient outcome under current conditions?\u201c In the pharmaceutical industry, this outcome is almost never purely cost-minimal. Supply, regulatory stability, delivery capability, and economic viability must be considered simultaneously.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Which levers must be considered together<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In practice, this means products must be segmented, markets prioritized, and material flows assessed on a differentiated basis. For a portfolio heavily dependent on the US market, it may be sensible to manage certain items differently than generic or less critical products. Active ingredients and critical starting materials should not be viewed in isolation but in conjunction with demand, release capacity, transport routes, and safety stocks.<\/p>

Often, the greatest leverage lies not in a radical shift, but in more precise allocation: a different transport or supply route, a modified packaging logic, a new prioritization of production slots, or a different allocation of scarce APIs. Operationally, this can make the difference between controlled margin pressure and a cascade of follow-on problems.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Further interesting content<\/p>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t